The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Academic Article

abstract

• Cannabis-derived cannabinoids such as cannabidiol (CBD) have anticonvulsant properties. Recently, there has been an emerging interest in the use of CBD-enriched products for treatment of drug-resistant epilepsy. Some pilot trials of CBD have proved beneficial for refractory epilepsy, but its efficacy is yet to be confirmed by standard placebo-controlled trials. However, the mechanisms underlying the seizure protection efficacy claims of CBD remain unclear. This review briefly describes the clinical utility of CBD in the treatment of refractory epilepsy.

authors

• Reddy, Samba

published proceedings

• Clin Pharmacol Ther

altmetric score

• 1.5

author list (cited authors)

• Reddy, D. S.

citation count

• 37

complete list of authors

• Reddy, DS

publication date

• February 2017

publisher

• Wiley  Publisher

published in

• Clinical Pharmacology and Therapeutics  Journal

keywords

• Animals
• Anticonvulsants
• Cannabidiol
• Clinical Trials As Topic
• Epilepsy
• Half-Life
• Humans
• Medical Marijuana
• Metabolic Clearance Rate
• Pilot Projects
• Receptor, Cannabinoid, Cb1
• Receptor, Cannabinoid, Cb2

PubMed Central ID

• 27506704

Digital Object Identifier (DOI)

• 10.1002/cpt.441

start page

• 182

end page

• 184

volume

• 101

issue

• 2

URL

• http://dx.doi.org/10.1002/cpt.441